Gwajin Maganin Halittar Halitta don Ciwon Jiyya na Ciwon Suga Ɗaya daga cikin Mafi yawan Labaran da aka sauke

A KYAUTA Kyauta 5 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Helixmith ya sanar a yau cewa littafin su, "Gene far for diabetic neuropathy: Wani bazuwar, nazarin wuribo-sarrafawa na III na VM202, DNA plasmid wanda ke ɓoye haɓakar haɓakar hanta na ɗan adam," yana ɗaya daga cikin manyan-10 mafi yawan abubuwan da aka sauke a cikin Clinical da Kimiyyar Fassara (CTS) a cikin 2021. CTS ita ce bugu na hukuma na American Society for Clinical Pharmacology & Therapeutics (ASCPT) kuma yana ba da haske game da bincike na asali wanda ke taimakawa gadar binciken dakin gwaje-gwaje tare da ganowa da magance cututtukan ɗan adam. Dokta John Kessler, Farfesa na Neurology a Arewa maso Yamma shine jagoran marubucin wannan binciken. Wannan shine kashi na 3 na Farko na Farko wanda aka taɓa yi don jin zafi. A cewar Alethea Gerding, Manajan Editan, ASCPT, “An zazzage labarin fiye da sau 3,000, ma’ana ya kai ga yawan masu karatu a duniya. Babban manufar CTS ita ce ta zama fitilar kimiyyar fassara, kuma labarai irin naku suna nuna a sarari darajar kimiyyar fassara."

A cikin takarda, VM202 (donaperminogene seltoplasmid), DNA na plasmid wanda ke ɓoye kwayar halittar HGF na ɗan adam (hepatocyte growth factor), wanda Helixmith Co. Ltd ya haɓaka, marubutan sun ruwaito cewa a cikin VMDN-003b, allurar intramuscular na VM202 ta ba da rage jin zafi fiye da 8. watanni bayan sake zagayowar jiyya na ƙarshe da kuma cewa aminci da haƙuri sun kasance masu dacewa sosai, daidai da karatun da suka gabata. Ɗaya daga cikin mafi mahimmancin binciken asibiti a cikin VMDN-003b da kuma nazarin lokaci na II shine VM202 ya fi tasiri a cikin batutuwa ba a kan pregabalin ko gabapentin ba, biyu daga cikin magungunan da aka tsara a filin DPN.

Wadannan sakamakon suna da muhimmiyar tasiri na asibiti kamar yadda fiye da mutane miliyan 4.2 a Amurka an san suna fama da DPN mai raɗaɗi kuma kusan marasa lafiya miliyan 1.3 ana la'akari da su a matsayin rashin ƙarfi, ma'ana a halin yanzu magunguna ba sa aiki a gare su (Painful Diabetic Neuropathy, GlobalData 2018) .

Helixmith ya ƙaddamar da gwaji na biyu na 3 na DPN, REGAiN-1A (VMDN-003-2), a cikin Amurka kuma suna yin niyya don sakin manyan sakamakon layi a ƙarshen 2022. Kamfanin yana shirin fara kashi na uku na 3 don DPN a rabi na biyu na 2022.

Mahimman bayanai na takarda CTS

• VM202 (donaperminogene seltoplasmid) shine aji na farko, mai mallakar mallaka, wanda ba na hoto ba, mai yuwuwar farfadowar kwayar halittar DNA na plasmid, daga yanayin dabbar da ba na asibiti ba.

• An gudanar da nazarin Phase 3 don DPN mai raɗaɗi a sassa biyu, ɗaya na watanni 9 (VMDN-003; batutuwa ɗari biyar) da ɗaya tare da ƙarin watanni 3 zuwa watanni 12 (VMDN-003b; 101 batutuwa).

• Tsaro da juriya na VM202 ya ci gaba da bayyana dacewa sosai, daidai da binciken da ya gabata.

• Wadannan sakamakon suna da muhimmiyar tasiri na asibiti kamar yadda aka san fiye da mutane miliyan 4.2 a Amurka suna fama da DPN mai raɗaɗi da kusan marasa lafiya miliyan 1.3 don yin watsi da cewa magunguna a halin yanzu ba sa aiki a gare su.

Game da Ciwon Ciwon Ciwon Jiki

DPN mai raɗaɗi cuta ce ta gama gari kuma mai raɗaɗi na ciwon sukari mellitus wanda ke da mummunan tasiri akan ingancin rayuwa, bacci, da yanayi. Hanyoyin kwantar da hankali na yanzu suna da kwantar da hankali kuma ba sa kaiwa ga hanyoyin da ke cikin DPN mai raɗaɗi. Bugu da ƙari, taimako na alamun sau da yawa yana iyakance, kuma yawancin marasa lafiya da DPN mai raɗaɗi suna amfani da opioids.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...